Latest monoclonal antibodies News

Lack of innovation set to undermine antibiotic performance and health gains
AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against Covid
TGA receives application for an increased dose of GlaxoSmithKline’s Covid treatment sotrovimab for BA.2 Omicron sublineage
Promising nose spray could prevent and treat Covid
AstraZeneca’s antibody combination, Evusheld▼ authorised for use
New hope for babies born with heart defect
Sotrovimab shown to cause Covid treatment-resistant mutations
AstraZeneca’s Evusheld Granted Provisional Approval For Pre-Exposure Prophylaxis Of Covid
TGA provisionally approves AstraZeneca’s combination therapy – for pre-exposure prevention of Covid
Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants
Study Reveals How Migraine Pain Signals Are Generated-and Blocked
Researchers Identify Osteoarthritis ‘Pain Pathway’
WHO recommends two new drugs to treat Covid
TGA grants provisional determination to AstraZeneca Pty Ltd for Covid prophylaxis and treatment, tixagevimab and cilgavimab
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant 23 December
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant
Evusheld long-acting antibody combination authorised for emergency use
New analyses of two AZD7442 Covid Phase III trials in high-risk populations confirm robust efficacy and long-term prevention
TGA grants provisional determination to AstraZeneca Pty Ltd for Covid preventative treatment, tixagevimab and cilgavimab
CSL Research and Development Day 2021
Research-industry partnership to advance biologic therapies
Australia secures additional Covid treatments
AZD7442 request for Emergency Use Authorization for Covid prophylaxis filed in US
Researchers Illuminate Working Mechanism of Important Drug Target Proteins
WHO prioritizes access to diabetes and cancer treatments in new Essential Medicines Lists
Melbourne-made Covid treatment could future-proof Australia